DBPOM

DBPOM (Database of Pharmaco-omics for Cancer Precision Medicine) integrates pharmaco-omics data to evaluate drug potency and adverse effects in cancer by assessing drug-induced gene expression changes and mapping cell lines to patients based on genetic mutation similarities.

Key Features:

• Comprehensive Drug Evaluation: Calculates drug potency by assessing the ability to reverse or enhance cancer-associated gene expression changes and implements reverse potency calculations.
• Patient-Specific Analysis: Maps cell lines to individual patients based on genetic mutation similarities to estimate drug effectiveness at the individual level.
• Single-Drug and Combination Analysis: Analyzes both single drugs and drug combinations for their overall effects on patients and the biological functions targeted by treatments.
• Support for Research Studies: Provides detailed analyses to support drug development, mechanism-of-action studies, and discovery of new therapies.

Scientific Applications:

• Drug development: Prioritizes compounds by predicted ability to reverse disease-associated gene expression and by evaluating potential adverse effects.
• Mechanism-of-action studies: Links drug-induced gene expression modulation to targeted biological functions for hypothesis generation on mechanisms.
• Discovery of new therapies: Facilitates identification of candidate drugs and combinations with favorable expression reversal profiles.
• Precision oncology: Informs individualized treatment selection by mapping cell line responses to patient mutation profiles.

Methodology:

Leverages pharmaco-omics data, maps cell lines to patients by genetic mutation similarities, and applies reverse potency calculations and gene expression modulation analyses to predict drug responses and potential adverse effects.